Hypertension After Renal Transplantation
Calcium Channel or Converting Enzyme Blockade?
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Abstract We compared the effects of 4 weeks of calcium channel blockade (amlodipine) or converting enzyme inhibition (lisinopril) on blood pressure and renal hemodynamics in a double-blind crossover trial in a group of 20 hypertensive cyclosporine-treated renal transplant patients. Amlodipine (10 mg) was more effective than the same dose of lisinopril in controlling hypertension (mean 24-hour arterial pressure, 111±9 and 115±9 mm Hg, respectively; P<.05). Blood pressure during both treatments was lower than during placebo (124±12 mm Hg, P<.05). Compared with placebo, amlodipine treatment was associated with a significant increase in glomerular filtration rate (10±20%, P<.05) and effective renal plasma flow (27±20%, P<.01) and a decrease in renal vascular resistance (23±18%, P<.01). Renal hemodynamics did not change during lisinopril. Neither drug had an effect on proteinuria. The data indicate that amlodipine is more effective than lisinopril in controlling hypertension in cyclosporine-treated patients and that treatment with amlodipine but not with lisinopril is accompanied by an increase in glomerular filtration rate and effective renal plasma flow and a decrease in renal vascular resistance. The data suggest that the renin-angiotensin system does not play a main role in determining cyclosporine-associated changes in renal hemodynamics and has a limited role in determining cyclosporine-associated hypertension.
- vascular resistance
- calcium channel blockers
- angiotensin-converting enzyme inhibitors
- kidney transplantation
- antihypertensive therapy
- Received August 8, 1994.
- Revision received September 8, 1994.
- Accepted October 3, 1994.